Keitern, I am aware this is happening across the small Biotechs' sector and MicroCaps in general.
However, the LFB deal had to be the turning point. GTCB had a great opportunity there. Either you sell your technology at the right price to the right people or you sell your technology at the wrong price to the wrong people. It now turns out to be the last and that is not the first time with this CFO.
The only good thing that happened to GTCB was LEO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.